When the US Food and Drug Administration (FDA) approves a new drug, federal law requires public disclosure of the review documents prepared by scientific disciplines (eg, clinical, toxicology, statistical) during the review.1 These scientific reviews are published on the FDA Drugs@FDA website (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm). In many cases, the data and analyses contained in those reviews have proved useful to public health.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Herder M, Morten CJ, Doshi P. Integrated Drug Reviews at the US Food and Drug Administration—Legal Concerns and Knowledge Lost. JAMA Intern Med. 2020;180(5):629–630. doi:10.1001/jamainternmed.2020.0074
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: